NIH R01 · 2025
Manufacture of defined live microbial therapeutics for infectious and inflammatory disease
PROJECT SUMMARY The approval of two fecal-based products for the treatment of recurrent Clostridioides difficile infection (rCDI) demonstrates the potential of microbial therapeutics to treat human disease. However, fecal-based products have a poorly defined safety profile that varies by fecal donor. In addition, fecal-based products are inherently not scalable as increasing drug production requires increasing stool donations provided by individual humans. Defined live biotherapeutic products (LBP) comprised of in vitro manufactured bacterial strains provide a scalable alternative to fecal products and ideally contain only the necessary active ingredients (i.e., bacterial strains) that are…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.